Autek China

Autek China EBITDA per Share

The EBITDA per Share of Autek China (300595.SZ) as of Nov 5, 2026 is 0.71 CNY. In the previous year, EBITDA per Share was 0.97 CNY — a change of -27.05% (lower).

EBITDA per Share

0.71CNY

YoY

-27.05%

Last updated:

EBITDA per Share of Autek China is 2025 0.71 CNY. EBITDA per Share of Autek China was 2024 0.97 CNY. It decreases by -27.05% lower compared to the previous year.

The Autek China EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.30 CNY
Jan 1, 2019
0.41 CNY
Jan 1, 2020
0.58 CNY
Jan 1, 2021
0.90 CNY
Jan 1, 2022
0.99 CNY
Jan 1, 2023
1.06 CNY
Jan 1, 2024
0.97 CNY
Jan 1, 2025
0.71 CNY
The Autek China EBITDA per Share history
YEAREBITDA per ShareYoY
0.71CNY-27.05%
0.97CNY-8.42%
1.06CNY+7.62%
0.99CNY+10.21%
0.90CNY+55.61%
0.58CNY+41.89%
0.41CNY+35.36%
0.30CNY+40.30%
0.21CNY+31.70%
0.16CNY+0.84%
0.16CNY+95.36%
0.08CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autek China Stock analysis

What does Autek China do? Autek China Inc. generates revenue through its main business of non-surgical vision correction, primarily selling orthokeratology products like Dream David, general contact lenses, and care products. The company also earns income from general glass frame sales, targeting domestic Chinese consumers. Its core product Dream David orthokeratology is a key revenue driver, while contact lenses and care products support the vision correction segment. The domestic market remains the primary sales channel for all product lines. The firm's product portfolio includes orthokeratology, general contact lenses, and care products as its main offerings, with Dream David being the flagship orthokeratology product. Glass frame sales represent a secondary revenue stream, though the company emphasizes its vision correction technology as the main focus. All products are sold within China, with no international markets mentioned in the business description. Autek China Inc. serves domestic Chinese customers seeking vision correction solutions without surgery, including those using orthokeratology and contact lenses. The company's revenue is derived from direct sales of its branded products, with Dream David orthokeratology being the most prominent. The domestic market segment is the sole focus, as the business description specifies no international operations or additional market segments. Autek China is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autek China stock

EBITDA per Share of Autek China is 0.71 CNY in 2025.

EBITDA per Share of Autek China changed from 0.97 CNY to 0.71 CNY, representing a -27.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Autek China since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Autek China

All Key Metrics — Autek China